1. Home
  2. PMAX vs HCWB Comparison

PMAX vs HCWB Comparison

Compare PMAX & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$0.56

Market Cap

3.4M

Sector

N/A

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.16

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
HCWB
Founded
2019
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.6M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
PMAX
HCWB
Price
$0.56
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.2M
751.6K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $4,099,750.00
Revenue This Year
N/A
$12,215.61
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.86
52 Week High
$4.81
$24.42

Technical Indicators

Market Signals
Indicator
PMAX
HCWB
Relative Strength Index (RSI) 35.95 26.99
Support Level $0.24 $1.14
Resistance Level $2.69 $1.73
Average True Range (ATR) 0.08 0.11
MACD -0.01 0.00
Stochastic Oscillator 11.84 1.70

Price Performance

Historical Comparison
PMAX
HCWB

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: